Results from a phase 1 clinical trial show that a broadly neutralizing, HIV-specific antibody is durably expressed in vivo from a viral vector, highlighting an alternate approach for the delivery of antibodies in humans.
- Joseph P. Casazza
- Evan M. Cale
- Kathy Zephir